IceCure Medical (ICCM) announced the completion of its last patients’ five-year follow up evaluation in its ICESECRET clinical trial of ProSense for the treatment of small renal masses in kidney cancer patients. ICESECRET, a prospective, multicenter, single-arm clinical trial, included 114 patients with localized SRMs of less than or equal to 5 cm ablated with ProSense cryoablation under CT guidance. Safety was determined by monitoring procedure-related adverse events throughout the study. ProSense is approved for benign and malignant kidney tumors in the U.S., Europe, and other countries
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical CFO to Step Down After Nearly Decade of Service as Succession Search Advances
- IceCure Medical announces departure of CFO Ronen Tsimerman
- IceCure Medical Reports Record 2025 ProSense® Sales Following Landmark FDA Breast Cancer Clearance
- IceCure Medical sees FY25 ProSense sales $3.4M
- IceCure Medical Extends Equity Distribution Agreement with Maxim Group to March 2026